Skip to main content

and
  1. Article

    Open Access

    Correction: Exploring the Effects of Ixekizumab on Pain in Patients with Ankylosing Spondylitis Based on Objective Measures of Inflammation: Post Hoc Analysis from a Large Randomized Clinical Trial

    Kurt de Vlam, Walter P. Maksymowych, Gaia Gallo, Proton Rahman in Rheumatology and Therapy (2024)

  2. Article

    Open Access

    Exploring the Effects of Ixekizumab on Pain in Patients with Ankylosing Spondylitis Based on Objective Measures of Inflammation: Post Hoc Analysis from a Large Randomized Clinical Trial

    The objective of this analysis is to evaluate the improvement in spinal pain with ixekizumab, placebo, and adalimumab based on objective measures of inflammation response in patients with ankylosing spondyliti...

    Kurt de Vlam, Walter P. Maksymowych, Gaia Gallo, Proton Rahman in Rheumatology and Therapy (2024)

  3. Article

    Open Access

    Benefits of Autoantibody Enrichment in Early Rheumatoid Arthritis: Analysis of Efficacy Outcomes in Four Pooled Abatacept Trials

    The efficacy of abatacept is enhanced in anti-citrullinated protein antibody (ACPA) and rheumatoid factor (RF)-positive versus -negative patients with rheumatoid arthritis (RA). Four early RA abatacept trials ...

    Kaleb Michaud, Philip G. Conaghan, Sang Hee Park in Rheumatology and Therapy (2023)

  4. Article

    Open Access

    Single and Composite Endpoints of Within-Patient Improvement in Symptoms: Pooled Tanezumab Data in Patients with Osteoarthritis

    Combining measures of key core domains (especially pain and function) into a composite endpoint that requires each patient to meet a threshold of improvement for each domain provides information on multiple as...

    Thomas J. Schnitzer, Francis Berenbaum, Philip G. Conaghan in Rheumatology and Therapy (2021)

  5. Article

    Open Access

    Individual Participant Symptom Responses to Intra-Articular Lorecivivint in Knee Osteoarthritis: Post Hoc Analysis of a Phase 2B Trial

    Established thresholds for patient-reported outcomes (PROs) provide clinically relevant responder data from trials. Lorecivivint (LOR) is an intra-articular (IA) therapy in development for knee osteoarthritis ...

    Jeyanesh R. S. Tambiah, Sarah Kennedy in Rheumatology and Therapy (2021)